Clinical trial
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of…
NCT00481559 · BTG International Inc., Other · Approved for marketing
Key facts
| NCT number | NCT00481559 |
|---|---|
| Title | Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity |
| Official title | An Open-Label Treatment Protocol for the Use of Voraxaze as Adjunctive Treatment for Patients Experiencing or at Risk of Methotrexate Toxicity |
| Lead sponsor | BTG International Inc., Other |
| Collaborators | CTI Clinical Trial and Consulting Services |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Voraxaze (glucarpidase) |
| First posted | Jun 1, 2007 |
| Last update posted | Jan 17, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: